Cell therapy for central nervous system disorders: Current obstacles to progress

Cell therapy for disorders of the central nervous system has progressed to a new level of clinical application. Various clinical studies are underway for Parkinson's disease, stroke, traumatic brain injury, and various other neurological diseases. Recent biotechnological developments in cell th...

Full description

Saved in:
Bibliographic Details
Published in:CNS neuroscience & therapeutics 2020-06, Vol.26 (6), p.595-602
Main Authors: Yasuhara, Takao, Kawauchi, Satoshi, Kin, Kyohei, Morimoto, Jun, Kameda, Masahiro, Sasaki, Tatsuya, Bonsack, Brooke, Kingsbury, Chase, Tajiri, Naoki, Borlongan, Cesario V., Date, Isao
Format: Article
Language:English
Subjects:
Angiogenesis
Apoptosis
Blood diseases
Cell adhesion & migration
Cell therapy
Central nervous system
Clinical trials
Dopamine
Drug discovery
Immunosuppressive agents
iPS cells
Mesenchyme
Movement disorders
Nervous system
Neurodegenerative diseases
Neurogenesis
Neurological diseases
Neurons
Parkinson's disease
Pathology
Pluripotency
Review
Stem cell transplantation
Stem cells
Stroke
Traumatic brain injury
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cell therapy for disorders of the central nervous system has progressed to a new level of clinical application. Various clinical studies are underway for Parkinson's disease, stroke, traumatic brain injury, and various other neurological diseases. Recent biotechnological developments in cell therapy have taken advantage of the technology of induced pluripotent stem (iPS) cells. The advent of iPS cells has provided a robust stem cell donor source for neurorestoration via transplantation. Additionally, iPS cells have served as a platform for the discovery of therapeutics drugs, allowing breakthroughs in our understanding of the pathology and treatment of neurological diseases. Despite these recent advances in iPS, adult tissue‐derived mesenchymal stem cells remain the widely used donor for cell transplantation. Mesenchymal stem cells are easily isolated and amplified toward the cells' unique trophic factor‐secretion property. In this review article, the milestone achievements of cell therapy for central nervous system disorders, with equal consideration on the present translational obstacles for clinic application, are described.
ISSN:1755-5930
1755-5949
DOI:10.1111/cns.13247